Clinical Trials on Liver Decompensation in Austria

Total 692 results

Janssen R&D Ireland

Completed

TMC435HPC3001 - An Efficacy, Safety and Tolerability Study for TMC435 vs Telaprevir in Combination With PegINFα-2a and Ribavirin in Chronic Hepatitis C Patients Who Were Null or Partial Responders to Prior PegINFα-2a and Ribavirin Therapy (ATTAIN)

Hepatitis C

United States, Australia, France, Poland, United Kingdom, Germany, Spain, Belgium, Israel, Portugal, Bulgaria, Romania, Denmark, Greece, Sweden, Canada, Czech Republic, Argentina, Brazil, Austria, Hungary, Switzerland, Puerto Rico, No...
Mitsubishi Tanabe Pharma America Inc.

Active, not recruiting

Extension Study to Evaluate Safety and Tolerability of Oral Dersimelagon (MT-7117) in Subjects With Erythropoietic Protoporphyria (EPP) or X-Linked Protoporphyria (XLP)

EPP | XLP

United States, Germany, Japan, Spain, Italy, Sweden, Australia, Canada, Norway, United Kingdom
Bristol-Myers Squibb

Completed

Phase 3 Efficacy and Safety Study of Peginterferon Lambda-1a and Ribavirin With Telaprevir (PEDESTAL)

Hepatitis C Virus

Belgium, Germany, Spain, United States, Canada, Brazil, Austria, France, Israel, Switzerland, Italy, Russian Federation, Czechia, Poland, United Kingdom
Brii Biosciences Limited
VBI Vaccines Inc.; Vir Biotechnology, Inc.

Completed

Study to Investigate the Safety and Efficacy of BRII-835 and BRII-179 Combination Therapy Treating Chronic Hepatitis B Virus (HBV) Infection

Hepatitis B, Chronic

Australia, China, Korea, Republic of, New Zealand, Singapore, Thailand
Hoffmann-La Roche

Completed

A Study of Danoprevir Boosted With Low Dose Ritonavir in Combination With Pegasys and Copegus in Treatment-Naive Patients With Chronic Hepatitis C Virus Infection

Hepatitis C, Chronic

France, Germany, United States, Spain, Canada, Austria, United Kingdom, Puerto Rico, Italy, Brazil, Mexico
Gilead Sciences

Completed

Efficacy, Safety, and Tolerability of Ledipasvir/Sofosbuvir (LDV/SOF) Treatment for HIV/HCV Co-infected Participants Who Switch to Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (E/C/F/TAF) or Emtricitabine/Rilpivirine/Tenofovir Alafenamide (F/R/TAF) Prior to LDV/SOF HCV Treatment (Co-STARs)

HIV-1 Infection | HCV Infection

United States, Puerto Rico
Gilead Sciences

Completed

Sofosbuvir With Pegylated Interferon and Ribavirin Hepatitis C Virus (HCV) Genotypes 1,4,5,6 (ATOMIC)

Hepatitis C, Chronic

United States, Puerto Rico
Human Genome Sciences Inc.
Novartis

Completed

Efficacy of Albumin Interferon Alfa-2b With Ribavirin Compared to Peg-IFN Alfa-2a With Ribavirin in IFN Naive Patients Geno2/3

Chronic Hepatitis C

Korea, Republic of, United States, Spain, Canada, France, Australia, Israel, Singapore, Thailand, Malaysia, Sweden, Belgium, Germany, Taiwan, Poland, Argentina, India, Puerto Rico, Brazil, Mexico, United Kingdom
University of North Carolina, Chapel Hill
University of Florida

Completed

HCV-TARGET- Hepatitis C Therapeutic Registry and Research Network

Hepatitis C

United States, Puerto Rico, Canada, Germany
Gilead Sciences
Quintiles, Inc.

Completed

Safety Study of Regimens of Sofosbuvir, GS-0938, and Ribavirin in Patients With Chronic Hepatitis C Infection (QUANTUM)

Hepatitis C, Chronic

United States, Puerto Rico
Mitsubishi Tanabe Pharma America Inc.

Completed

Study to Evaluate Efficacy, Safety, and Tolerability of MT-7117 in Subjects With Erythropoietic Protoporphyria or X-Linked Protoporphyria

EPP | XLP

Spain, United States, Germany, Norway, Italy, Australia, Canada, Japan, Sweden, United Kingdom
Janssen R&D Ireland

Completed

An Efficacy, Safety, and Tolerability Study of TMC435 in Treatment-naive, Genotype 1 Hepatitis C-infected Patients (QUEST-1)

Hepatitis C

United States, Australia, Ukraine, United Kingdom, Germany, Spain, Mexico, Canada, New Zealand, Russian Federation, Puerto Rico, Romania
AbbVie

Completed

A Study of of Glecaprevir/Pibrentasvir in Adults With Chronic Hepatitis C Virus (HCV) Genotype 5 or 6 Infection (ENDURANCE-5 6)

Hepatitis C Virus (HCV)

United States, Australia, Belgium, Canada, France, New Zealand, Singapore, South Africa, Vietnam
Hologic, Inc.

Completed

Collection of Plasma and Serum Samples From Individuals Initiating Sofosbuvir for Chronic Hepatitis C for Testing

Hepatitis C

United States, Puerto Rico
Boehringer Ingelheim

Completed

Phase 3 Study of BI 207127 in Combination With Faldaprevir and Ribavirin for Treatment of Patients With Hepatitis C Infection, Including Patients Who Are Not Eligible to Receive Peginterferon: HCVerso2

Hepatitis C, Chronic

United States, Australia, Belgium, Canada, France, Germany, Greece, Italy, New Zealand, Portugal, Spain, United Kingdom
Children's Oncology Group
National Cancer Institute (NCI)

Completed

Sodium Thiosulfate in Preventing Hearing Loss in Young Patients Receiving Cisplatin for Newly Diagnosed Germ Cell Tumor, Hepatoblastoma, Medulloblastoma, Neuroblastoma, Osteosarcoma, or Other Malignancy

Sarcoma | Ovarian Cancer | Brain Tumor | Ototoxicity | Neuroblastoma | Liver Cancer | Central Nervous System Tumor | Extragonadal Germ Cell Tumor | Childhood Germ Cell Tumor

Canada, United States, Australia
Gilead Sciences

Completed

Safety and Efficacy of Sofosbuvir/Velpatasvir/Voxilaprevir in Adults With Chronic HCV Infection Who Have Previously Received Treatment With Direct-Acting Antiviral Therapy (POLARIS-1)

Hepatitis C

United States, France, United Kingdom, Germany, Australia, Canada, New Zealand, Puerto Rico
Hoffmann-La Roche

Completed

A Study to Collect Blood Biomarker Samples From Participants With Chronic Hepatitis B (CHB) Who Received Treatment With Pegasys (Peginterferon Alfa-2a) ± Nucleoside/Nucleotide Analogue

Hepatitis B, Chronic

Thailand, China, Italy, United Kingdom, Korea, Republic of, Taiwan, Austria, Bulgaria, Germany, New Zealand, France, Poland, Portugal, Romania, Greece
Janssen-Cilag International NV

No longer available

Early Access Program of Telaprevir With Peginterferon and Ribavirin in Chronic Hepatitis C Subjects

Hepatitis C

Australia, Belgium, Germany, Spain, Switzerland, Romania, Serbia, Greece, New Zealand, Brazil, Russian Federation, Austria, Hungary, Czech Republic, Luxembourg
Novartis Pharmaceuticals

Terminated

3-year Follow-up Study to Assess the Viral Activity in Hepatitis C Patients Who Failed Feeder DEB025/Alisporivir Study

Hepatitis C, Chronic

Romania, Italy, Germany, Belgium, Spain, Australia, Thailand, United States, Hungary, Taiwan, Poland, Canada, Puerto Rico, Vietnam, Korea, Republic of, India
Hoffmann-La Roche

Completed

Peak Study - A Study of Pegasys (Peginterferon Alfa-2a (40KD)) in Combination With Copegus (Ribavirin) in Interferon-Naive Patients With Chronic Hepatitis C (CHC).

Hepatitis C, Chronic

United States
Baxalta now part of Shire
Baxalta Innovations GmbH, now part of Shire

Terminated

Stage 1 Study of ARALAST NP and GLASSIA in A1PI Deficiency

Chronic Obstructive Pulmonary Disease | Alpha1-antitrypsin Deficiency

United States, Canada, Australia
Arbutus Biopharma Corporation

Active, not recruiting

Open-Label Study of AB-729, Nucleos(t)Ide Analogue and Pegylated Interferon Alfa-2a in Subjects With Chronic Hepatitis B Infection

Chronic Hepatitis b

United States, Korea, Republic of, Hong Kong, Taiwan, Australia, Moldova, Republic of, Ukraine
Brii Biosciences Limited
Vir Biotechnology, Inc.

Active, not recruiting

Investigate the Efficacy and Safety of BRII-835 (VIR-2218) and PEG-IFNα Combination Therapy in Chronic HBV Patients

Chronic Hepatitis B Virus Infection

Singapore, Thailand, Australia, China, Korea, Republic of
Debiopharm International SA

Completed

Efficacy and Safety of Adding Alisporivir (DEB025) to Peginterferon (IFN) Alfa-2a (Peg-IFN Alfa-2a) and Ribavirin in Chronic HCV Genotype 1 Patients Who Relapsed or Did Not Respond to Previous Treatment

Hepatitis C

Romania, Italy, Hungary, Taiwan, Turkey, Belgium, Spain, Germany, Australia, France, United States, United Kingdom, Poland, Puerto Rico
Novartis Pharmaceuticals
Merck Sharp & Dohme LLC

Completed

Telbivudine in Adults Previously Treated in Idenix-Sponsored Telbivudine Studies

Chronic Hepatitis B

United States, Australia, Canada, China, Czechia, France, Germany, Hong Kong, India, Israel, Italy, Korea, Republic of, New Zealand, Poland, Puerto Rico, Singapore, Spain, Taiwan, Thailand, Turkey, United Kingdom
Novartis
Human Genome Sciences Inc.

Completed

Safety and Efficacy of Albumin Interferon Administered Every 4 Weeks in Genotype 2/3 Hepatitis C Patients

Chronic Hepatitis C

Taiwan, Germany, Greece, Italy, Spain, United Kingdom, France, Canada, Australia, India, Poland, Thailand
AbbVie

Completed

Efficacy and Safety of Glecaprevir (ABT-493)/Pibrentasvir (ABT 530) (GLE/PIB) in Combination With Sofosbuvir and Ribavirin in Participants With Hepatitis C Virus Who Did Not Respond to Treatment in a Previous AbbVie Clinical Study (MAGELLAN-3)

Hepatitis C Virus Infection

United States, Australia, Canada, China, Germany, Korea, Republic of, New Zealand, Russian Federation, Spain, Sweden, Switzerland, United Kingdom
Janssen Infectious Diseases BVBA

Completed

Efficacy and Safety Study of Simeprevir in Combination With Sofosbuvir in Participants With Genotype 1 Chronic Hepatitis C Virus Infection and Cirrhosis

Hepatitis C Virus Infection

United States, Canada
SciClone Pharmaceuticals

Completed

Thymosin Plus PEG-Interferon in Hepatitis C Patients With Cirrhosis Who Did Not Respond to Interferon or Interferon Plus Ribavirin

Hepatitis C | Hepatitis C, Chronic

United States, Puerto Rico
Alexion Pharmaceuticals, Inc.

Terminated

Study of ALXN1840 Versus Standard of Care in Pediatric Participants With Wilson Disease

Wilson Disease

Spain, Korea, Republic of, France, Germany, Japan, Australia, Poland, United Kingdom
Bristol-Myers Squibb

Completed

Antiviral Activity of Entecavir in Patients Receiving Liver Transplant Due to Chronic Hepatitis B Virus Infection

Hepatitis B, Chronic

Argentina, France, Italy, Korea, Republic of, Taiwan, United States, Spain, Australia, Brazil
Hoffmann-La Roche

Completed

A Study of PEGASYS (Peginterferon Alfa-2a (40KD)) in Patients With Hepatitis Be Antigen (HBeAg) Positive Chronic Hepatitis B (CHB).

Hepatitis B, Chronic

China, Hong Kong, Australia, Germany, Taiwan, Singapore, France, United States, Korea, Republic of, New Zealand, Thailand, Russian Federation, Brazil
Merck Sharp & Dohme LLC

Recruiting

Pembrolizumab Plus Lenvatinib in Combination With Belzutifan in Solid Tumors (MK-6482-016)

Carcinoma, Hepatocellular | Colorectal Neoplasms | Esophageal Neoplasms | Endometrial Neoplasms | Pancreatic Ductal Adenocarcinoma | Biliary Tract Neoplasms

Israel, United States, Australia, Belgium, Chile, France, Korea, Republic of, Netherlands, Spain, New Zealand
Gilead Sciences

Completed

A Study to Compare Tenofovir DF Versus the Combination of Emtricitabine Plus Tenofovir DF for the Treatment of Chronic Hepatitis B in Patients With Normal Alanine Aminotransferase (ALT)

Chronic Hepatitis B

Taiwan, France, Germany, Hong Kong, United States, Canada, New Zealand, Australia, Singapore, Poland, United Kingdom
Gilead Sciences

Completed

A Study of Response-Guided Duration of Combination Therapy With GS-9451, Pegasys® and Copegus® With and Without Tegobuvir (GS-9190) in Previously Untreated Subjects With Genotype 1 Chronic Hepatitis C

Hepatitis C, Chronic

United States, United Kingdom, France, Germany, Netherlands, Belgium, Austria, Poland
Hoffmann-La Roche

Completed

An Observational Study of Peginterferon (e.g. Pegasys)-Based Direct Acting Antiviral Triple Therapy in Patients With Chronic Hepatitis C Genotype 1

Hepatitis C, Chronic

United States, Puerto Rico
Gilead Sciences

Completed

Safety and Efficacy of SOF/VEL/VOX FDC for 8 Weeks and SOF/VEL for 12 Weeks in Adults Chronic Genotype 3 HCV Infection and Cirrhosis (POLARIS-3)

Hepatitis C Virus Infection

United States, France, United Kingdom, Germany, Australia, Canada, New Zealand, Puerto Rico
GlaxoSmithKline

Completed

Immunogenicity & Safety of Hepatitis A Vaccine Co-admin With a Measles/Mumps/Rubella & a Varicella Vaccine in Children

Hepatitis A

United States
Gilead Sciences

Completed

Study to Compare Tenofovir Alafenamide (TAF) Versus Tenofovir Disoproxil Fumarate (TDF) in Participants With Chronic Hepatitis B Infection Who Are Positive for Hepatitis B e Antigen

HBeAg-positive Chronic Hepatitis B

Hong Kong, Korea, Republic of, United States, Taiwan, United Kingdom, France, Australia, Spain, Bulgaria, Canada, India, Italy, Japan, New Zealand, Poland, Romania, Russian Federation, Singapore, Turkey
Hoffmann-La Roche

Completed

A Study of Pegasys (Peginterferon Alfa-2a) Administered Alone or in Combination With Copegus (Ribavirin) in Patients With Chronic Hepatitis C Who Have Participated in Previous Pegasys Trials

Hepatitis C, Chronic

Australia, United States, Italy, France, Puerto Rico, Taiwan, United Kingdom, Greece, Poland, Brazil, Spain
Boehringer Ingelheim

Completed

Efficacy and Safety of BI 201335 (Faldaprevir) in Combination With Pegylated Interferon-alpha and Ribavirin in Treatment-naïve Genotype 1 Hepatitis C Infected Patients (STARTverso 2)

Hepatitis C

United States, Canada, Korea, Republic of, Puerto Rico, Taiwan
Janssen Infectious Diseases BVBA
Vertex Pharmaceuticals Incorporated

Completed

VX-950-C211 - A Dosing Regimen Study (Twice Daily Versus Every 8 Hours) of Telaprevir in Treatment-naïve Participants With Genotype 1 Chronic Hepatitis C Virus Infection

Genotype 1 Chronic Hepatitis C | Treatment Naive

United States, Australia, France, Poland, United Kingdom, Belgium, Germany, Spain, Sweden, Brazil, Austria, Ireland, Mexico
Gilead Sciences

Completed

A Phase 3, Open-label Study to Investigate the Efficacy and Safety of Sofosbuvir Plus Ribavirin in Chronic Genotype 1, 2, 3 and 4 Hepatitis C Virus (HCV) and Human Immunodeficiency Virus (HIV) Co-infected Adults

Chronic Hepatitis C | Human Immunodeficiency Virus

France, Italy, United Kingdom, Germany, Spain, Australia
Gilead Sciences

Terminated

Long Term Follow-up Registry of Individuals Treated in A Gilead-Sponsored Trial in Individuals With Chronic Hepatitis B Infection

Chronic Hepatitis B

New Zealand, Korea, Republic of, Hong Kong, United States, Canada, Australia, Italy, India
Gilead Sciences

Completed

Safety and Efficacy of SOF/VEL/VOX FDC for 12 Weeks and SOF/VEL for 12 Weeks in DAA-Experienced Adults With Chronic HCV Infection Who Have Not Received an NS5A Inhibitor (POLARIS-4)

Hepatitis C Virus Infection

United States, France, United Kingdom, Germany, Canada, Australia, New Zealand, Puerto Rico
Alnylam Pharmaceuticals

Completed

EXPLORE: A Natural History Study of Acute Hepatic Porphyria (AHP)

Acute Hepatic Porphyria

United States, Belgium, Bulgaria, France, Italy, Mexico, Spain, Taiwan, United Kingdom, Netherlands, Korea, Republic of, Switzerland, Czechia, Poland, Finland, Australia, Germany, Israel, Norway, South Africa
GlaxoSmithKline

Completed

Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Engerix™-B in Adults With or Without Type 2 Diabetes Mellitus

Hepatitis B

United States, Australia, Canada, New Zealand
Debiopharm International SA

Completed

Long Term Follow-up Study to Assess Durability of Sustained Virologic Response in Alisporivir-treated Hepatitis C Patients

Hepatitis C

Romania, Italy, Belgium, Germany, Hungary, Taiwan, Spain, Australia, Hong Kong, Thailand, France, United States, United Kingdom, Turkey, Argentina, Russian Federation, India, Korea, Republic of, Vietnam, Poland, Mexico, Canada
Grifols Therapeutics LLC

Enrolling by invitation

Long Term Safety of Alpha1-Proteinase Inhibitor in Subjects With Alpha1 Antitrypsin Deficiency (SPARTA-OLE)

Pulmonary Emphysema in Alpha-1 Antitrypsin Deficiency

United States, New Zealand, Denmark, Australia, Finland, Estonia, Canada, Poland, Russian Federation, Sweden, France

Clinical Trials on Liver Decompensation in Austria

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Philippines

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations